Wie hoch ist der Preis für Clover Biopharmaceuticals, Ltd. (2197)

Preis für Clover Biopharmaceuticals, Ltd. (2197) ist $0.25841098

Wie hoch ist die Marktkapitalisierung für Clover Biopharmaceuticals, Ltd. (2197)

Marktkapitalisierung für Clover Biopharmaceuticals, Ltd. (2197) ist $335.38M

Clover Biopharmaceuticals, Ltd. (2197) Umsatz

Clover Biopharmaceuticals, Ltd. is a biotechnology enterprise focused on discovering, developing, and commercializing innovative vaccines and biological therapies. Their efforts target infectious diseases, various cancers, and autoimmune conditions. The company's pipeline features several key candidates: SCB-2019 (CpG 1018/Alum): A COVID-19 vaccine candidate currently advancing through Phase II/III clinical trials. SCB-313: A trimeric fusion protein aimed at treating severe intracavitary malignancies, including malignant ascites, malignant pleural effusions, and peritoneal carcinomatosis, addressing a significant global medical need. SCB-808: Undergoing pivotal Phase III clinical trials for the management of rheumatic disorders. SCB-420: An aflibercept biosimilar in preclinical development for ophthalmologic conditions like wet age-related macular degeneration. SCB-219: A novel TPOR agonist in preclinical stages for the treatment of chemotherapy-induced thrombocytopenia and immune thrombocytopenic purpura. Clover also holds a collaboration and supply agreement with Dynavax, which provides its CpG 1018 adjuvant for use in preclinical studies. The company was established in 2007 and is based in Shanghai, China.

Jahr	Umsatz	ändert
Nicht genügend Daten für die angegebenen Daten.

Jahr

Umsatz

ändert

Nicht genügend Daten für die angegebenen Daten.

Unternehmen	Umsatz	Umsatzunterschied	Land
Vertex Pharmaceuticals Incorporated VRTX.US	$12.62B	-	US
Argenx SE ARGX.US	$6.02B	-	NL
Moderna, Inc. MRNA.US	$2.23B	-	US
CSL Limited CSL.AX	$15.74B	-	AU
Lonza Group AG LONN.SW	-	-	CH

Unternehmen

Umsatz

Umsatzunterschied

Land